ProQR Therapeutics (PRQR) Projected to Release Quarterly Earnings on Thursday

ProQR Therapeutics (NASDAQ:PRQR) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect ProQR Therapeutics to post earnings of ($0.11) per share and revenue of $4.30 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.04. The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $4.56 million. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%. On average, analysts expect ProQR Therapeutics to post ($0.45) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

ProQR Therapeutics Price Performance

Shares of NASDAQ PRQR opened at $1.32 on Tuesday. ProQR Therapeutics has a 1 year low of $1.20 and a 1 year high of $2.81. The firm has a 50-day simple moving average of $1.74 and a two-hundred day simple moving average of $1.69.

Wall Street Analyst Weigh In

PRQR has been the topic of several recent research reports. Bank of America initiated coverage on shares of ProQR Therapeutics in a report on Thursday, August 20th. They set a “buy” rating and a $8.00 target price on the stock. Weiss Ratings upgraded shares of ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research report on Thursday, October 1st. Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, HC Wainwright cut their price objective on shares of ProQR Therapeutics to $8.00 and set a “buy” rating on the stock in a report on Thursday, October 1st. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.60.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA therapies for genetic diseases. The company uses its Axiomer RNA-editing platform to investigate treatments designed to correct disease-causing genetic changes at the RNA level without permanently altering DNA.

ProQR’s research has included therapies for rare inherited disorders, particularly genetic diseases affecting the eye and nervous system. Its development programs have included investigational treatments for inherited retinal diseases, while the company has also pursued partnerships and licensing opportunities to advance RNA-editing applications across additional disease areas.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR serves the global biotechnology and pharmaceutical markets through its research, development and strategic collaborations.